Global Stock News

Corvus Stock: Soquelitinib Q1 Interim Futility Analysis AD Drug Advancement (NASDAQ:CRVS)

Corvus Stock: Soquelitinib Q1 Interim Futility Analysis AD Drug Advancement (NASDAQ:CRVS)

This article was written by

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it…

Source link

Share this article

Scroll to Top